1.Gastric cancer presenting with ramucirumab-related gastrocolic fistula successfully managed by colonic stenting: a case report
Hiroki FUKUYA ; Yoichiro IBOSHI ; Masafumi WADA ; Yorinobu SUMIDA ; Naohiko HARADA ; Makoto NAKAMUTA ; Hiroyuki FUJII ; Eikichi IHARA
Clinical Endoscopy 2023;56(6):812-816
We report a rare case of gastric cancer presenting with a gastrocolic fistula during ramucirumab and paclitaxel combination therapy that was successfully managed with colonic stenting. A 75-year-old man was admitted to our hospital with the chief complaint of melena. Esophagogastroduodenoscopy revealed a large ulcerated tumor in the lower stomach, judged by laparoscopy as unresectable (sT4bN1M0). After four cycles of first-line chemotherapy with S-1 plus oxaliplatin, the patient showed disease progression, and second-line therapy with ramucirumab and paclitaxel was started. At the end of the third cycle, the patient had gastric antral stenosis, which necessitated the placement of a gastroduodenal stent. When the patient complained of diarrhea 10 days later, esophagogastroduodenoscopy revealed a fistula between the greater curvature of the stomach and the transverse colon. The fistula was covered by double colonic stenting, with a covered metal stent placed within an uncovered metal stent, after which leakage from the stomach to the colon stopped.
2.A Case of Suspicious Allergic Reaction to Peracetic Acid Following Endoscopy
Naohiko HARADA ; Manami HIROWATARI ; Eikichi IHARA ; Etsuko ISHIHARA ; Mitsuko INOUE ; Tomoya MIYAMURA ; Makoto NAKAMUTA
Clinical Endoscopy 2020;53(6):743-745
A 43-year-old man with rheumatic arthritis was admitted to our hospital for symptoms of cough, left chest pain, and left elbow pain, and further examination revealed an elevated level of C-reactive protein. On day 2 after admission, he underwent esophagogastroduodenoscopy. On the morning of day 7, he developed a high fever of 39.7°C, several hours after bronchoscopy. On day 13, he underwent colonoscopy. Five minutes after the colonoscopy, he developed a high fever of 39.9°C, accompanied by stridor, indicating a decrease in arterial oxygen saturation level. An intradermal test for peracetic acid which was used for cleaning flexible endoscopy was positive. We suspect that he suffered from an allergic reaction to peracetic acid following the flexible endoscopy. This is the first case reported on suspicious allergic reaction to peracetic acid following a flexible endoscopy procedure.
3.Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Kazuhiko NAKAMURA ; Eikichi IHARA ; Hirotada AKIHO ; Kazuya AKAHOSHI ; Naohiko HARADA ; Toshiaki OCHIAI ; Norimoto NAKAMURA ; Haruei OGINO ; Tsutomu IWASA ; Akira ASO ; Yoichiro IBOSHI ; Ryoichi TAKAYANAGI
Gut and Liver 2016;10(6):917-924
BACKGROUND/AIMS: The ability of endoscopic submucosal dissection (ESD) to resect large early gastric cancers (EGCs) results in the need to treat large artificial gastric ulcers. This study assessed whether the combination therapy of rebamipide plus a proton pump inhibitor (PPI) offered benefits over PPI monotherapy. METHODS: In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66). The Scar stage (S stage) ratio after treatment was compared, and factors independently associated with ulcer healing were identified by using multivariate analyses. RESULTS: The S stage rates at 4 and 8 weeks were similar in the two groups, even in the subgroups of patients with large amounts of tissue resected and regardless of CYP2C19 genotype. Independent factors for ulcer healing were circumferential location of the tumor and resected tissue size; the type of treatment did not affect ulcer healing. CONCLUSIONS: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).
Adenoma
;
Cicatrix
;
Cytochrome P-450 CYP2C19
;
Endoscopy
;
Genotype
;
Humans
;
Multivariate Analysis
;
Prospective Studies
;
Proton Pump Inhibitors
;
Proton Pumps*
;
Protons*
;
Rabeprazole
;
Stomach Neoplasms
;
Stomach Ulcer*
;
Ulcer
4.Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Kazuhiko NAKAMURA ; Eikichi IHARA ; Hirotada AKIHO ; Kazuya AKAHOSHI ; Naohiko HARADA ; Toshiaki OCHIAI ; Norimoto NAKAMURA ; Haruei OGINO ; Tsutomu IWASA ; Akira ASO ; Yoichiro IBOSHI ; Ryoichi TAKAYANAGI
Gut and Liver 2016;10(6):917-924
BACKGROUND/AIMS: The ability of endoscopic submucosal dissection (ESD) to resect large early gastric cancers (EGCs) results in the need to treat large artificial gastric ulcers. This study assessed whether the combination therapy of rebamipide plus a proton pump inhibitor (PPI) offered benefits over PPI monotherapy. METHODS: In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66). The Scar stage (S stage) ratio after treatment was compared, and factors independently associated with ulcer healing were identified by using multivariate analyses. RESULTS: The S stage rates at 4 and 8 weeks were similar in the two groups, even in the subgroups of patients with large amounts of tissue resected and regardless of CYP2C19 genotype. Independent factors for ulcer healing were circumferential location of the tumor and resected tissue size; the type of treatment did not affect ulcer healing. CONCLUSIONS: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer (UMIN Clinical Trials Registry, UMIN000007435).
Adenoma
;
Cicatrix
;
Cytochrome P-450 CYP2C19
;
Endoscopy
;
Genotype
;
Humans
;
Multivariate Analysis
;
Prospective Studies
;
Proton Pump Inhibitors
;
Proton Pumps*
;
Protons*
;
Rabeprazole
;
Stomach Neoplasms
;
Stomach Ulcer*
;
Ulcer
5.The feasibility of percutaneous transhepatic gallbladder aspiration for acute cholecystitis after self-expandable metallic stent placement for malignant biliary obstruction: a 10-year retrospective analysis in a single center
Akihisa OHNO ; Nao FUJIMORI ; Toyoma KAKU ; Masayuki HIJIOKA ; Ken KAWABE ; Naohiko HARADA ; Makoto NAKAMUTA ; Takamasa OONO ; Yoshihiro OGAWA
Clinical Endoscopy 2022;55(6):784-792
Background/Aims:
Patients with acute cholecystitis (AC) after metallic stent (MS) placement for malignant biliary obstruction (MBO) have a high surgical risk. We performed percutaneous transhepatic gallbladder aspiration (PTGBA) as the first treatment for AC. We aimed to identify the risk factors for AC after MS placement and the poor response factors of PTGBA.
Methods:
We enrolled 401 patients who underwent MS placement for MBO between April 2011 and March 2020. The incidence of AC was 10.7%. Of these 43 patients, 37 underwent PTGBA as the first treatment. The patients’ responses to PTGBA were divided into good and poor response groups.
Results:
There were 20 patients in good response group and 17 patients in poor response group. Risk factors for cholecystitis after MS placement included cystic duct obstruction (p<0.001) and covered MS (p<0.001). Cystic duct obstruction (p=0.003) and uncovered MS (p=0.011) demonstrated significantly poor responses to PTGBA. Cystic duct obstruction is a risk factor for cholecystitis and poor response factor for PTGBA, whereas covered MS is a risk factor for cholecystitis and an uncovered MS is a poor response factor of PTGBA for cholecystitis.
Conclusions
The onset and poor response factors of AC after MS placement were different between covered and uncovered MS. PTGBA can be a viable option for AC after MS placement, especially in patients with covered MS.
6.Characteristics of Hemorrhagic Peptic Ulcers in Patients Receiving Antithrombotic/Nonsteroidal Antiinflammatory Drug Therapy.
Kazuhiko NAKAMURA ; Kazuya AKAHOSHI ; Toshiaki OCHIAI ; Keishi KOMORI ; Kazuhiro HARAGUCHI ; Munehiro TANAKA ; Norimoto NAKAMURA ; Yoshimasa TANAKA ; Kana KAKIGAO ; Haruei OGINO ; Eikichi IHARA ; Hirotada AKIHO ; Yasuaki MOTOMURA ; Teppei KABEMURA ; Naohiko HARADA ; Yoshiharu CHIJIIWA ; Tetsuhide ITO ; Ryoichi TAKAYANAGI
Gut and Liver 2012;6(4):423-426
BACKGROUND/AIMS: Antithrombotic/nonsteroidal antiinflammatory drug (NSAID) therapies increase the incidence of upper gastrointestinal bleeding. The features of hemorrhagic peptic ulcer disease in patients receiving antithrombotic/NSAID therapies were investigated. METHODS: We investigated the medical records of 485 consecutive patients who underwent esophagogastroduodenoscopy and were diagnosed with hemorrhagic gastroduodenal ulcers. The patients treated with antithrombotic agents/NSAIDs were categorized as the antithrombotic therapy (AT) group (n=213). The patients who were not treated with antithrombotics/NSAIDs were categorized as the control (C) group (n=263). The clinical characteristics were compared between the groups. RESULTS: The patients in the AT group were significantly older than those in the C group (p<0.0001). The hemoglobin levels before/without transfusion were significantly lower in the AT group (8.24+/-2.41 g/dL) than in the C group (9.44+/-2.95 g/dL) (p<0.0001). After adjusting for age, the difference in the hemoglobin levels between the two groups remained significant (p=0.0334). The transfusion rates were significantly higher in the AT group than in the C group (p=0.0002). However, the outcome of endoscopic hemostasis was similar in the AT and C groups. CONCLUSIONS: Patients with hemorrhagic peptic ulcers receiving antithrombotic/NSAID therapies were exposed to a greater risk of severe bleeding that required transfusion but were still treatable by endoscopy.
Anti-Inflammatory Agents, Non-Steroidal
;
Endoscopy
;
Endoscopy, Digestive System
;
Hemoglobins
;
Hemorrhage
;
Hemostasis, Endoscopic
;
Humans
;
Incidence
;
Medical Records
;
Peptic Ulcer